Results 101 to 110 of about 151,635 (354)

[Retracted] Effect of Dapagliflozin on Clinical Outcome after Drug‐Eluting Stent Implantation in Elderly T2DM Patients: A Real‐World Study [PDF]

, 2023
Yuan Lin, Fang Zhou, Xihu Wang, Yaju Guo, Weiguo Chen   +4 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation [PDF]

, 2012
Tomohisa Tada, Masahiro Natsuaki, Takeshi Morimoto, Yutaka Furukawa, Yoshihisa Nakagawa, Robert A. Byrne, Adnan Kastrati, Kazushige Kadota, Masashi Iwabuchi, Satoshi Shizuta, Junichi Tazaki, Hiroki Shiomi, Mitsuru Abe, Natsuhiko Ehara, Tetsu Mizoguchi, Hirokazu Mitsuoka, Tsukasa Inada, Makoto Araki, Satoshi Kaburagi, Ryoji Taniguchi, Hiroshi Eizawa, Akira Nakano, Satoru Suwa, Akinori Takizawa, Ryuji Nohara, Hisayoshi Fujiwara, Kazuaki Mitsudo, Masakiyo Nobuyoshi, Toru Kita, Takeshi Kimura   +29 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Development of coronary stents using advanced results of materials science and technology [PDF]

, 2004
Stents are high tech endovascular implants. K&M Inc. is the single Eastern European stent producer company. The market needs more biocompatible devices as the trend of the stent development all the producers have to react.
Dobránszky, János, Major, L., Nyitrai, Zs., Puskás, Zs.   +3 more
core  

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

EVA implants for controlled drug delivery to the inner ear

International Journal of Pharmaceutics: X
This study evaluated the potential of poly(ethylene vinyl acetate) (EVA) copolymers as matrix formers in miniaturised implants, allowing to achieve controlled drug delivery into the inner ear.
Y. Bedulho das Lages, N. Milanino, J. Verin, J.F. Willart, F. Danede, C. Vincent, P. Bawuah, J.A. Zeitler, F. Siepmann, J. Siepmann   +9 more
doaj   +1 more source

Development of Implants for Prolonged Drug delivery

British Journal of Pharmacy, 2019
Despite being a popular and convenient route of drug delivery, the oral route has a number of disadvantages. Polymeric sub-dermal implants offer an alternative delivery route that may circumvent many of these challenges.
Sarah Anne Stewart, Ryan F Donnelly, Eneko Larrañeta   +2 more
doaj   +1 more source

Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation [PDF]

, 2009
Fumiyuki Hayashi, Raisuke Iijima, Masato Nakamura, Kaoru Sugi   +3 more
openalex   +1 more source